


## Azoramide

<b>Cat. No.:</b>	HY-18705												
<b>CAS No.:</b>	932986-18-0												
<b>Molecular Formula:</b>	C <sub>15</sub> H <sub>17</sub> ClN <sub>2</sub> O <sub>2</sub> S												
<b>Molecular Weight:</b>	308.83												
<b>Target:</b>	Apoptosis; Reactive Oxygen Species; Caspase; Bcl-2 Family; Mitochondrial Metabolism												
<b>Pathway:</b>	Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB												
<b>Storage:</b>	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>2 years</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 year</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	2 years		-20°C	1 year
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	2 years											
	-20°C	1 year											



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 30 mg/mL (97.14 mM)  
 Ethanol : 2 mg/mL (6.48 mM; Need ultrasonic)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.2380 mL	16.1901 mL	32.3803 mL
	5 mM	0.6476 mL	3.2380 mL	6.4761 mL
	10 mM	0.3238 mL	1.6190 mL	3.2380 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (8.10 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (8.10 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (8.10 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Azoramide is a potent, orally active small-molecule modulator of the unfolded protein response (UPR). Azoramide improves ER protein folding and elevates ER chaperone capacity, which together protects cells against ER stress. Azoramide alleviates PLA2G6 mutant-induced ER stress through modulating unfolded protein response, and enhances the CERB signaling to rescue mitochondrial function, thereby preventing apoptosis of DA neurons. Azoramide has antidiabetic activity<sup>[1][2]</sup>.

**In Vitro**

Azoramide (0.01-100  $\mu\text{M}$ ; 0-24 h; Huh7 cells) regulates ER folding and secretion capacity without inducing ER stress<sup>[1]</sup>. Azoramide (15  $\mu\text{M}$ ; 2-16 h; Huh7 cells) protects cells from induced ER stress. Azoramide counteracts [Tunicamycin](#) (Tm, HY-A0098)-induced ATF6LD-Cluc secretion and Tm-induced decrease of ASGR-Cluc secretion. Azoramide suppresses Tm-induced GRP78 and CHOP protein expression<sup>[1]</sup>. Azoramide (15  $\mu\text{M}$ ; 2-16 h; Hepa 1-6 cells) alters ER calcium homeostasis and retains a greater fraction of  $\text{Ca}^{2+}$  in the ER<sup>[1]</sup>. Azoramide (0-10  $\mu\text{M}$ ; 5 d) attenuates loss of PLA2G6<sup>D331Y/D331Y</sup> iPSC-derived midbrain DA neurons<sup>[2]</sup>. Azoramide (10  $\mu\text{M}$ ; 5 d) reduces the increase in ROS and ameliorates the decline in mitochondrial membrane potential in PLA2G6<sup>D331Y/D331Y</sup> midbrain DA neurons<sup>[2]</sup>. Azoramide (10  $\mu\text{M}$ ; 0-30 d) suppresses mitochondrial fragmentation in PLA2G6<sup>D331Y/D331Y</sup> midbrain DA neurons<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[2]</sup>

Cell Line:	DA neurons
Concentration:	0, 0.1, 0.3, 1, 3, and 10 $\mu\text{M}$
Incubation Time:	5 days
Result:	Enhanced cell viability with 27 and 39% for 3 and 10 $\mu\text{M}$ , respectively.

Western Blot Analysis<sup>[2]</sup>

Cell Line:	DA neurons
Concentration:	10 $\mu\text{M}$
Incubation Time:	24 hours
Result:	Decreased the cleaved level of caspase 3 and the ratio of Bax/Bcl2 in PLA2G6 mutant neurons. Enhanced expression of CREB in PLA2G6 mutant neurons.

Western Blot Analysis<sup>[2]</sup>

Cell Line:	DA neurons
Concentration:	10 $\mu\text{M}$
Incubation Time:	30 days
Result:	Suppressed increased expression of UPR proteins, elevated the decreased expression level of mfn1, and inhibited the elevated expression levels of DRP1 and Fis1 in PLA2G6 mutant neurons

**In Vivo**

Azoramide (150 mg/kg; p.o.; daily, for 7 d; Huh7 cells; ob/ob mice) improves glucose homeostasis in mice with genetic obesity and preserves beta cell function and survival during metabolic ER stress<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ob/ob mice (9-12 weeks of age) <sup>[1]</sup>
Dosage:	150 mg/kg
Administration:	Oral administration; daily, for 7 days
Result:	Reduces ER stress and improves metabolism in ob/ob mice. Increased the levels of Pdx1 mRNA and improved beta cell function.

---

## CUSTOMER VALIDATION

- Cell Prolif. 2021 Sep 28;e13133.
- Stem Cell Res Ther. 2018 Mar 9;9(1):57.
- Free Radic Biol Med. 2023 Aug 23;S0891-5849(23)00601-9.
- J Biol Chem. 2020 Feb 28;295(9):2713-2723.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

- [1]. Fu S, et, al. Phenotypic assays identify azoramide as a small-molecule modulator of the unfolded protein response with antidiabetic activity. Sci Transl Med. 2015 Jun 17;7(292):292ra98.
- [2]. Ke M, et, al. Azoramide protects iPSC-derived dopaminergic neurons with PLA2G6 D331Y mutation through restoring ER function and CREB signaling. Cell Death Dis. 2020 Feb 18;11(2):130.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA